Kaloban

Pelargonium sidoides root extract, the active ingredient in Kaloban, is a herbal medicine presented as an oral liquid extract for oral use. Derived from the dried root of Pelargonium sidoides and standardized for its bioactive constituents, it is employed to support relief of symptoms associated with acute bronchitis and other upper respiratory tract infections in adults and children.

GNH USA supplies Kaloban as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable global distribution.

Kaloban, containing Pelargonium sidoides root extract, is used to address conditions within the acute respiratory infection family.

Acute bronchitis: helps alleviate cough, sputum production and chest discomfort. Common cold: may reduce nasal congestion and throat irritation. Sinusitis: supports drainage and eases facial pressure. Upper respiratory tract infection: assists in overall symptom relief and promotes faster recovery.

Kaloban may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Mild gastrointestinal upset - Altered taste perception - Headache - Dizziness - Mild skin rash - Transient increase in heart rate

Serious or Rare Side Effects: - Anaphylactic allergic reaction - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Elevated liver enzymes - Acute renal impairment - Severe hypotension - Leukopenia

When using Kaloban, consider the following safety measures.

Pregnancy: safety not established; avoid unless benefits outweigh risks. Breastfeeding: insufficient data; use with caution. Children: dosage determined by healthcare professional; monitor for adverse reactions. Concomitant immunosuppressants: may reduce efficacy; monitor clinical response. Allergy: discontinue if hypersensitivity occurs. Store at ambient temperature below 25°C: keep in original container, protect from moisture and direct sunlight.

Kaloban may interact with other medicines; review the following categories.

Major Interactions (Avoid): - Anticoagulants: may increase bleeding risk. - Immunosuppressive agents: potential reduction in therapeutic effect. - CYP450 substrates: possible altered metabolism.

Moderate Interactions (Monitor Closely): - Antihistamines: may enhance sedative effect. - CYP3A4 inhibitors: may increase plasma levels of extract constituents. - Other immune‑stimulating herbal products: monitor for additive effects.